FIELD: medicine, immunology.
SUBSTANCE: invention relates to compositions and method for immunosuppression achievement. Claimed compositions contain two main agents: namely the first agent targeted to interleukin-15 receptor (IL-15R), and the second agent which inhibits costimulating signal transferred between T-cell and antigen-presenting cell (APC).
EFFECT: diagnosis and therapy of immune deceases, in particular autoimmune deceases with improved effectiveness.
45 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF IL-5 AND IL-MEDIATED CELL RESPONSES | 2001 |
|
RU2280255C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | 2015 |
|
RU2764074C2 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| INTERLEUKINE-15 PEPTIDE ANTAGONIST | 2005 |
|
RU2396276C2 |
| CONDITIONALLY ACTIVE CHIMERIC ANTIGENIC RECEPTORS FOR MODIFIED T CELLS | 2016 |
|
RU2759957C2 |
| INTERLEUKIN-2 (IL2R) AND INTERLEUKIN-2 (IL2) RECEPTOR VARIANTS FOR SPECIFIC ACTIVATION OF IMMUNE EFFECTOR CELLS | 2020 |
|
RU2832154C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
